XPK: [(1~{R})-1-[(3~{S},5~{S},8~{R},9~{S},10~{S},13~{S},17~{R})-3-methanoyloxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,13,14,15,16,17-hexadecahydrocyclopenta[a]phenanthren-17-yl]ethyl]-methylidyne-azanium
XPK is a Ligand Of Interest in 8FDA designated by the Author
| Best-fitted instance in this entry |
| Other instances in this entry |
| Identifier | Ranking for goodness of fit | Ranking for geometry | Real space R factor | Real space correlation coefficient | RMSZ-bond-length | RMSZ-bond-angle | Outliers of bond length | Outliers of bond angle | Atomic clashes | Stereochemical errors | Model completeness | Average occupancy |
|---|
| 8FDA_XPK_A_601 | 29% | 3% | 0.251 | 0.912 | 5.1 | 1.56 | 17 | 5 | 1 | 0 | 100% | 1 |
| 8FDA_XPK_B_601 | 23% | 2% | 0.276 | 0.901 | 5.15 | 1.71 | 16 | 8 | 2 | 0 | 100% | 1 |
| 8FDA_XPK_D_601 | 11% | 2% | 0.313 | 0.837 | 5.17 | 1.85 | 15 | 12 | 2 | 0 | 100% | 1 |
| 8FDA_XPK_C_601 | 11% | 2% | 0.33 | 0.845 | 5.1 | 1.86 | 16 | 10 | 3 | 0 | 100% | 1 |
| 8FDA_XPK_D_602 | 3% | 2% | 0.407 | 0.727 | 5.06 | 2.08 | 15 | 17 | 3 | 0 | 100% | 0.832 |
| 8FDA_XPK_C_602 | 0% | 2% | 0.502 | 0.551 | 5.13 | 2.01 | 15 | 13 | 0 | 0 | 100% | 0.818 |
